PEMQX
Price
$14.62
Change
+$0.07 (+0.48%)
Updated
Dec 20 closing price
RNWFX
Price
$77.72
Change
+$0.12 (+0.15%)
Updated
Dec 20 closing price
Ad is loading...

PEMQX vs RNWFX

Header iconPEMQX vs RNWFX Comparison
Open Charts PEMQX vs RNWFXBanner chart's image
Putnam Emerging Markets Equity R6
Price$14.62
Change+$0.07 (+0.48%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$77.72
Change+$0.12 (+0.15%)
VolumeN/A
CapitalizationN/A
PEMQX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
PEMQX vs. RNWFX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PEMQX is a Hold and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 62.2B vs. PEMQX (383M). RNWFX pays higher dividends than PEMQX: RNWFX (1.51) vs PEMQX (1.12). PEMQX was incepted earlier than RNWFX: PEMQX (7 years) vs RNWFX (23 years). PEMQX is a more actively managed with annual turnover of: 63.00 vs. RNWFX (32.00). PEMQX has a lower initial minimum investment than RNWFX: PEMQX (0) vs RNWFX (250). PEMQX annual gain was more profitable for investors over the last year : 18.48 vs. RNWFX (5.86). PEMQX return over 5 years is better than : 18.33 vs. RNWFX (14.39).
PEMQXRNWFXPEMQX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence7 years23 years-
Gain YTD16.4944.549363%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets383M62.2B1%
Annual Yield % from dividends1.121.5174%
Returns for 1 year18.485.86315%
Returns for 3 years-7.55-5.10148%
Returns for 5 years18.3314.39127%
Returns for 10 yearsN/A42.67-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VTRS12.520.39
+3.22%
Viatris
TEO11.890.14
+1.19%
Telecom Argentina SA
DX12.570.14
+1.13%
Dynex Capital
INTT7.680.04
+0.52%
inTEST Corp
VIRX0.21N/A
-1.87%
Viracta Therapeutics